The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib

Por Medina, Theresa M, Lewis, Karl D
Publicado no Onco Targets Ther (2016)

Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review

Por Okuyama, Sonia, Gonzalez, Rene, Lewis, Karl D
Publicado em 2010

Therapeutic options in cutaneous melanoma: latest developments

Por Amaria, Rodabe N., Lewis, Karl D., Gonzalez, Rene
Publicado em 2011

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma

Por Chang, Anne Lynn S., Lewis, Karl D., Arron, Sarah T., Migden, Michael R., Solomon, James A., Yoo, Simon, Day, Bann-Mo, McKenna, Edward F., Sekulic, Aleksandar
Publicado no Oncotarget (2016)

Long-term Follow-up and Survival of Patients Following a Recurrence of Melanoma After a Negative Sentinel Lymph Node Biopsy Result

Por Jones, Edward L., Jones, Teresa S., Pearlman, Nathan W., Gao, Dexiang, Stovall, Robert, Gajdos, Csaba, Kounalakis, Nicole, Gonzalez, Rene, Lewis, Karl D., Robinson, William A., McCarter, Martin D.
Publicado em 2013

Side Population Cells from Human Melanoma Tumors Reveal Diverse Mechanisms for Chemoresistance

Por Luo, Yuchun, Ellis, Lixia Z, Dallaglio, Katiuscia, Takeda, Moe, Robinson, William A, Robinson, Steven, Liu, Weimin, Lewis, Karl D, McCarter, Martin D, Gonzalez, Rene, Norris, David A, Roop, Dennis R, Spritz, Richard A, Ahn, Natalie G, Fujita, Mayumi
Publicado em 2012

Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors

Por Jimeno, Antonio, Weiss, Glen J., Miller, Wilson H., Gettinger, Scott, Eigl, Bernard J.C., Chang, Anne Lynne S., Dunbar, Joi, Devens, Shannon, Faia, Kerrie, Skliris, Georgios, Kutok, Jeff, Lewis, Karl D., Tibes, Raoul, Sharfman, William H., Ross, Robert W., Rudin, Charles M.
Publicado em 2013

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

Por Sekulic, Aleksandar, Migden, Michael R., Oro, Anthony E., Dirix, Luc, Lewis, Karl D., Hainsworth, John D., Solomon, James A., Yoo, Simon, Arron, Sarah T., Friedlander, Philip A., Marmur, Ellen, Rudin, Charles M., Chang, Anne Lynn S., Low, Jennifer A., Mackey, Howard M., Yauch, Robert L., Graham, Richard A., Reddy, Josina C., Hauschild, Axel
Publicado no N Engl J Med (2012)

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

Por Kim, Kevin B., Kefford, Richard, Pavlick, Anna C., Infante, Jeffrey R., Ribas, Antoni, Sosman, Jeffrey A., Fecher, Leslie A., Millward, Michael, McArthur, Grant A., Hwu, Patrick, Gonzalez, Rene, Ott, Patrick A., Long, Georgina V., Gardner, Olivia S., Ouellet, Daniele, Xu, Yanmei, DeMarini, Douglas J., Le, Ngocdiep T., Patel, Kiran, Lewis, Karl D.
Publicado no J Clin Oncol (2013)

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

Por Sosman, Jeffrey A., Kim, Kevin B., Schuchter, Lynn, Gonzalez, Rene, Pavlick, Anna C., Weber, Jeffrey S., McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Hersey, Peter, Kefford, Richard, Lawrence, Donald, Puzanov, Igor, Lewis, Karl D., Amaravadi, Ravi K., Chmielowski, Bartosz, Lawrence, H. Jeffrey, Shyr, Yu, Ye, Fei, Li, Jiang, Nolop, Keith B., Lee, Richard J., Joe, Andrew K., Ribas, Antoni
Publicado em 2012

Activity of the MEK Inhibitor Trametinib (GSK1120212) in Advanced Melanoma in a Phase I, Dose-escalation Trial

Por Falchook, Gerald S, Lewis, Karl D, Infante, Jeffrey R, Gordon, Michael S, Vogelzang, Nicholas J, DeMarini, Douglas J, Sun, Peng, Moy, Christopher, Szabo, Stephen A., Roadcap, Lori T, Peddareddigari, Vijay G R, Lebowitz, Peter F, Le, Ngocdiep T, Burris, Howard A, Messersmith, Wells A, O'Dwyer, Peter J, Kim, Kevin B., Flaherty, Keith, Bendell, Johanna C., Gonzalez, Rene, Kurzrock, Razelle, Fecher, Leslie A
Publicado em 2012